Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): final results from a phase 2, multicenter, open-label study (DESTINY-CRC01)

Autores: Yoshino, T.; Di Bartolomeo, M.; Raghav, K. P. S.; Masuishi, T.; Kawakami, H.; Yamaguchi, K.; Nishina, T.; Wainberg, Z. A.; Elez, E.; Rodríguez Rodríguez, Javier; Fakih, M.; Ciardiello, F.; Saxena, K.; Kobayashi, K.; Bako, E.; Okuda, Y.; Meinhardt, G.; Grothey, A.; Siena, S.